Cancer immunotherapy takes a different path from surgery, chemotherapy or radiation: instead of attacking the tumor directly, it retrains the body’s own immune system to find and destroy cancer cells. The most established form — immune checkpoint inhibitors — has transformed the outlook for cancers that were once considered untreatable, and in some patients it has produced durable, years-long remissions. Here is how it works, what it treats, and how patients can access it through Medical E-Aid.

What is cancer immunotherapy?

Immunotherapy is a class of treatment that uses the immune system to fight disease. The immune system normally patrols the body for abnormal cells, but cancer cells develop ways to hide from it or switch it off. Immunotherapy removes those disguises and re-activates the immune response, so the body can recognise cancer as a threat again. Because it works with the immune system rather than poisoning fast-dividing cells indiscriminately, it can reach cancer cells anywhere in the body — and, when it works, the protection can last long after treatment ends.

How immune checkpoint inhibitors work

Immune checkpoints are natural “brakes” on the immune system. They exist to stop immune cells from attacking healthy tissue. Cancer cells exploit these brakes: by activating checkpoint proteins such as PD-1 / PD-L1 and CTLA-4, they send an “off” signal to the T cells that would otherwise destroy them.

Checkpoint inhibitors are lab-made antibodies that block this signal. They do not kill cancer cells directly — they release the brakes, freeing T cells to find and attack the tumor. Approved checkpoint drugs fall into three groups: PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab), PD-L1 inhibitors (atezolizumab, durvalumab, avelumab) and the CTLA-4 inhibitor ipilimumab. They are usually given as an intravenous infusion every few weeks.

Other types of immunotherapy

Checkpoint inhibitors are the most widely used, but immunotherapy is a broad family that also includes:

• CAR T-cell therapy — a patient’s own T cells are collected, genetically engineered to recognise the cancer, multiplied, and returned to the body. Used mainly in certain blood cancers.
• Monoclonal antibodies — lab-made proteins that flag cancer cells for destruction or deliver a drug or radioactive particle directly to them.
• Cancer treatment vaccines — designed to prime the immune system against specific cancer targets.
• Cytokines and TILs — proteins and tumor-infiltrating lymphocytes that boost or redirect the immune attack.

What does immunotherapy treat?

Checkpoint inhibitors are now approved across a wide and growing range of cancers, including melanoma, non-small cell lung cancer, kidney cancer, bladder and urothelial cancers, head and neck cancers, Hodgkin lymphoma, liver cancer, and tumors with specific genetic features (such as high microsatellite instability) regardless of where they start. Suitability depends on the tumor type, stage, and often on biomarkers like PD-L1 expression, so eligibility is always confirmed by an oncology team.

What the outcomes show

Immunotherapy is notable not just for extending life but for producing durable responses in a subset of patients. In advanced melanoma, the CheckMate 067 trial — the longest follow-up of a checkpoint inhibitor in any cancer — reported a 10-year median overall survival of about 72 months for combined nivolumab plus ipilimumab, versus roughly 37 months for nivolumab alone and 20 months for ipilimumab alone. Among patients who were alive and progression-free at three years, 10-year melanoma-specific survival reached 96–97% — a level of long-term control that was almost unheard of in metastatic melanoma before immunotherapy.

In advanced lung cancer, the KEYNOTE-024 trial found that first-line pembrolizumab roughly doubled five-year survival compared with chemotherapy — about 32% versus 16% — in patients whose tumors had high PD-L1 expression. Results vary by cancer type and by individual, but these figures illustrate why immunotherapy has become a cornerstone of modern oncology.

The benefits at a glance

• Body-wide reach — activated immune cells can pursue cancer wherever it has spread
• Durable responses — some patients maintain control for years after stopping treatment
• Often better tolerated than chemotherapy, with a different side-effect profile
• Works across many cancers — and increasingly in combination with other therapies
• Outpatient delivery — most infusions do not require a hospital stay

What to expect

Treatment begins with a full assessment: imaging, pathology and often biomarker testing to confirm the cancer is likely to respond. Checkpoint inhibitors are then given as an infusion, typically every two to six weeks, over months. Because the treatment activates the immune system, side effects differ from chemotherapy — they can include inflammation of the skin, gut, thyroid, lungs or other organs, and are managed by an experienced team who monitor closely. Most patients continue normal daily life between infusions.

Accessing immunotherapy with Medical E-Aid

Immunotherapy requires specialist oncology centres with the expertise to select the right drug, run the necessary biomarker testing, and manage immune-related side effects. Medical E-Aid connects patients with leading, internationally equipped cancer centres and coordinates the whole journey: a medical review of your case, a treatment plan and cost estimate, and full support with travel, visas, interpretation and aftercare. Our AI pre-screening helps match your specific diagnosis to the right specialist and clinic.

This article is for general information only and is not medical advice. Immunotherapy is not suitable for every patient or every cancer; suitability depends on each patient’s diagnosis and biomarkers and must be determined by qualified specialists. Outcome figures are drawn from published clinical trials and may not reflect individual results.

Sources: National Cancer Institute (NCI), Immunotherapy for Cancer & Immune Checkpoint Inhibitors; American Cancer Society; CheckMate 067 10-year results, New England Journal of Medicine (2025); KEYNOTE-024 5-year results, Journal of Clinical Oncology (2021).